Clinical Trails

The Phase 3 SunRISE-2 study tested a new bladder drug-delivery system, Gem-iDRS, combined with the immunotherapy drug cetrelimab, in patients with muscle-invasive bladder cancer (MIBC) who did not undergo bladder removal. Gem-iDRS releases chemotherapy directly into the bladder over several weeks, while the control group received standard chemoradiotherapy (CRT), which combines radiation with systemic chemotherapy. […]

The RETAIN-1 and RETAIN-2 trials studied a new “risk-adapted” approach for treating muscle-invasive bladder cancer (MIBC). Instead of automatically removing the bladder with radical cystectomy, researchers wanted to find out which patients could safely keep their bladder through careful monitoring. In this approach, patients first received chemotherapy (MVAC) combined with immunotherapy (nivolumab) before surgery. Their

The Phase 3 KEYNOTE-B15/EV-304 trial compared a new treatment combination with standard cisplatin-based chemotherapy for patients with muscle-invasive bladder cancer (MIBC). For the first time in 25 years, a non-platinum regimen performed better than the usual cisplatin plus gemcitabine treatment. Patients received either enfortumab vedotin (EV) plus pembrolizumab before and after surgery, or cisplatin plus

The Phase 2 BRCAAway trial shows that combining abiraterone, prednisone, and olaparib is far more effective than using either drug alone for patients with metastatic castration-resistant prostate cancer who have BRCA1/2 or ATM mutations. Patients receiving the three-drug combination lived a median of 68 months—over five years—compared with 28 months for abiraterone alone and 37

Starton Therapeutics has treated the first patient in a Phase 2a study (NCT06087653) testing STAR-LLD, a new continuous under-the-skin (subcutaneous) form of lenalidomide, for people with relapsed or refractory multiple myeloma. Lenalidomide, sold as Revlimid, is commonly taken by mouth and is a standard treatment for multiple myeloma. However, when taken orally, the drug reaches

The phase 3 AEWS1031 study found that in patients with nonmetastatic Ewing sarcoma treated with interval-compressed chemotherapy, the choice of local treatment—surgery, radiation, or both—did not independently affect the risk of the cancer returning in the same area. The overall 5-year local recurrence rate was low at 6%, reflecting major improvements in modern, multi-modality care.

Early results from an ongoing Phase 2 trial (NCT07222579) show that a subcutaneous (under-the-skin) form of blinatumomab (Blincyto) may be highly effective and well tolerated for mixed phenotype acute leukemia (MPAL), a rare and aggressive blood cancer. The first patient treated, a 77-year-old with Philadelphia chromosome–negative MPAL, achieved a complete response after just one 26-day

The SWOG S1512 Phase 2 trial studied giving pembrolizumab (Keytruda) before surgery to patients with resectable desmoplastic melanoma, a rare type of skin cancer usually found on sun-exposed areas. After just three doses of pembrolizumab, 71% of patients had no cancer left in their surgical tissue samples. At three years, 74% of patients had no

A phase 1/2 study evaluated tagraxofusp (Elzonris), a CD123-targeted therapy, as a single-agent treatment for patients with myelofibrosis. The drug showed modest clinical benefit but was generally well tolerated, with no dose-limiting toxicities reported. These findings suggest tagraxofusp may be better suited for use in combination with other therapies rather than as a standalone treatment.

Global trials are showing strong promise for PARP inhibitors as a new targeted treatment for advanced prostate cancer. Prostate cancer is the second most common cancer in men, with about 1.5 million new cases yearly and numbers expected to rise to 2.4 million by 2040. While early-stage prostate cancer has nearly a 100% 5-year survival